The global Peptide Therapeutics market size is expected to be worth around US$ 58.04 billion by 2030, according to a new report by Vision Research Reports.
The global Peptide Therapeutics market size was valued at US$ 31.5 billion in 2020 and is anticipated to grow at a CAGR of 19.4% during forecast period 2021 to 2030.
Growth Factors
Increasing demand for efficient & rapid-acting therapeutics for treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, are anticipated to propel market growth.
Rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives. Moreover, growing base of geriatric population is expected to widen the consumer base by triggering incidence rate of target diseases such as cancer & diabetes, which are expected to drive the demand for peptide therapeutics.
Technological advancements in peptide manufacturing process is one of the major factors driving the market growth during the forecast period. Manufacturers and suppliers are focusing on the adoption of novel technologies to manufacture efficient drug molecules with low time and capital investment. Improvement in purification & automation process and less generation of waste is an additional factor attributing toward market growth
Report Highlights
The cancer segment dominated in 2020 with revenue generation of over USD 1.85 billion. Increasing the prevalence of cancer worldwide and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for dominance in this segment.
Increasing demand for efficient and rapid-acting therapeutics is further anticipated to accentuate growth. Increased awareness amongst patients & healthcare professionals regarding adverse effects of chemotherapy and radiation therapy is a high rendering factor for growing focus toward alternative therapeutics such as peptide-based drugs. The aforementioned reason is expected to push cancer as an application with the fastest growth rate. Moreover, the presence of a strong product pipeline is anticipated to affirm progress.
The incidence of metabolic disorders is increasing at a fast rate. Increasing adoption of a sedentary lifestyle, unhealthy food habits, and consumption of a high amount of alcohol have led to increased occurrence of these disorders. Moreover, the increasing base of the geriatric population susceptible to metabolic disorders is estimated to provide the market with a potential growth platform.
The market is classified based on the type of drugs into generic and innovative drugs. The innovative peptides dominated in 2020 and held a share of around 66.93%, owing to the increasing investments by large pharmaceuticals in R&D for the development of novel drugs and high prescription rates.
However, generics are anticipated to witness lucrative growth over the forecast period. Rising expenditure on healthcare and increasing healthcare expenditure by the federal government is expected to propel the adoption of generics.
The loss of patents of many branded drugs is also estimated as a key factor responsible for the growth of the generics segment. Patent loss is considered as a big opportunity for generic players to enter the market with low-cost alternatives for blockbuster drugs. However, brand loyalty in case of some innovative drugs may impact the segment flourishment
The in-house manufacturing segment held the largest share accounting for over 60.0% in 2020. Most of the key players are involved in developing peptide therapeutics in-house owing to stringent regulations and high cost of outsourcing. As large pharmaceutical companies have proper infrastructure for large-scale production and advanced technology, these companies prefer in-house manufacturing.
The outsourcing activities for manufacturing are also estimated to boom during the forecast period due to difficulties in manufacturing therapeutics with high-quality standards. The companies prefer to outsource the Active Pharmaceutical Ingredient (API) from companies having high-end technology and expertise for manufacturing various types of peptides.
Peptide manufacturing is a complex procedure and it requires advanced technology such as Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), or Hybrid for purification and synthesis of high-quality products, which results into the high cost of manufacturing. Besides, increasing R&D funding and capital investments by key players by entering into strategic agreements is anticipated to result in the market growth over the forecast period.
The biopharmaceuticals giants are continuously exploring new methods of drug delivery pertinent to peptides. Novel drug delivery technologies are now being assessed for efficacy with engineered molecules having advanced PEGylation, in an attempt to improve drug delivery performance and patient compliance through better modes of drug delivery.
Patient compliance and acceptability are major advantages of the oral route of drug administration. However, enzymatic degradation that inhibits blood absorption of these drugs holds a major disadvantage. Parenteral route of administration dominated in 2016 with a substantial amount of share. This dominance is attributed mainly to the high adoption rate, faster delivery of drugs, and ease of application.
The pulmonary route is acknowledged for peptide and protein administration owing to the physiological characteristics of the respiratory system. Several proteins and peptides are currently undergoing clinical trials and awaiting approval via pulmonary usage. However, low bioavailability and lower molecular weighing molecules crossing alveolar epithelium causing inflammation are major usage barriers.
However, other routes such as intradermal and nasal are expected to grow at a lucrative CAGR of over 14.0% over the forecast period. The bioavailability of the nasal route was found to be over 4.0%, giving it an edge over the oral route. Also, enzymatic degradation of the peptide is avoided by transdermal and nasal route.
The LPPS segment dominated with a share of over 45.0% in 2020 owing to the presence of rising demand for pure peptides for the development of efficient therapeutics. However, issues such as higher consumption of time are responsible for shifting consumers’ preference to faster and effective methods such as SPPS.
SPPS lowers the synthesis time and is used in a wide range of production procedures. Moreover, higher efficiency during the synthesis of longer peptides is another driver for the market. Furthermore, associated automation, scalability, and enhanced control over the physicochemical properties of peptides are expected to drive the market over the forecast period.
Hybrid technology is expected to spearhead growth owing to associated benefits such as compatibility with both liquid-phase synthesis and solid-phase synthesis. Companies are investing in R&D to incorporate the benefits of both LPSS & SPSS and to provide a cost-effective and sustainable solution. Advanced hybrid technology is expected to grow at a lucrative CAGR of over 12.0% owing to a high adoption rate.
North America dominated the market in 2020. The rise in awareness levels about peptide therapeutics products, increasing demand for diagnostics in cancer & other diseases, and growing biotechnology industry are the factors contributing toward the dominance. Increasing R&D expenditure by the government is also estimated to help peptide therapeutics maintain dominance over the coming years. A well-established biopharmaceutical & pharmaceutical industry in this region is a major factor responsible for growth.
On the other hand, Asia Pacific is expected to register considerable growth over the forecast period owing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector. Cheaper cost of raw materials and patent expiration of blockbuster drugs boosting generic market is expected to provide significant growth opportunities shortly.
Key Players
Eli Lilly and Company; Pfizer, Inc.; Amgen, Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceuticals Industries Ltd.; Lonza Inc.; Sanofi; Bristol-Myers Squibb (BMS); AstraZeneca PLC; GlaxoSmithKline plc (GSK); Novartis AG; and Novo Nordisk A/S
Market Segmentation
Application Outlook
Metabolic
Cardiovascular Disorder
Respiratory
GIT
Anti-infection
Pain
Dermatology
CNS
Renal
Others
Type Outlook
Generic
Innovative
Type of Manufacturers Outlook
In-house
Outsourced
Route of Administration Outlook
Parenteral Route
Oral Route
Pulmonary
Mucosal
Others
Synthesis Technology
Solid Phase Peptide Synthesis (SPPS)
Liquid Phase Peptide Synthesis (LPPS)
Hybrid Technology
Regional Outlook
North America
The U.S.
Canada
Europe
Germany
UK
Asia Pacific
China
Japan
India
Latin America
Mexico
Brazil
MEA
South Africa
The Peptide Therapeutics market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Peptide Therapeutics market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Peptide Therapeutics market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Peptide Therapeutics market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Peptide Therapeutics market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Peptide Therapeutics capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Peptide Therapeutics by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Peptide Therapeutics market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Peptide Therapeutics market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Peptide Therapeutics market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Peptide Therapeutics industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Peptide Therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Peptide Therapeutics market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Peptide Therapeutics market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Peptide Therapeutics market. These factors have benefited the growth of the global market for Peptide Therapeutics. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Peptide Therapeutics. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Peptide Therapeutics are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
Primary Sources
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers